340B Drug Pricing Program
In comments on OPPS proposed rule, AHA urges HHS to immediately reverse 340B cuts
The Issue:
Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for patients in vulnerable communities. These organizations include public and nonprofit…
The AHA submitted comments on the Centers for Medicare & Medicaid Services’ outpatient prospective payment system and ambulatory surgical center payment system proposed rule for calendar year 2021.
AHA comments on the Centers for Medicare & Medicaid Services’ hospital outpatient prospective payment system and ambulatory surgical center payment system proposed rule for calendar year 2020.
Appeals Court Urged to Reconsider Decision Upholding 340B Hospital Payment Cuts
New Analysis Shows 340B Tax-exempt Hospitals Provided More Than $64B in Benefits to Communities
AHA seeks rehearing of U.S. appeals court decision on cuts to 340B hospitals
The AHA and other national health care groups yesterday urged the Department of Health and Human Services to protect 340B hospitals and the vulnerable communities they serve “from actions taken by five of the nation’s largest pharmaceutical manufacturers that undermine access to critical drugs and…
The AHA today sent letters to the heads of U.S.
The Department of Health and Human Services in a strongly worded letter to Eli Lilly calls into question recent actions by the drug manufacturer to limit 340B hospital and community clinics’ use of 340B contract pharmacy arrangements.